ESG

Weight Watchers now offers the new Wegovy pill, a needle-free option, betting its future on combining powerful GLP-1 drugs with its classic support.

New AMA codes for PolarityBio's SkinTE signal a strategic step toward commercialization, aiming to ease clinical adoption for chronic wound care.

Circle Pharma will unveil its pipeline of novel oral macrocycle drugs targeting elusive cancer drivers at the influential J.P. Morgan Healthcare Conference.

AMC Robotics establishes a new manufacturing hub in Ho Chi Minh City, a strategic move to scale its Kyro robot and join the global tech shift to Vietnam.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

South Korea's Curogen secures major national funding and targets global partners at the JP Morgan conference, advancing novel therapies for IBD and HS.

A new 10,000-sample 'skin library' collected by painless stickers aims to slash drug development time and costs for biopharmaceutical partners.

Prenetics slashed future dilution risk by exchanging 4.7M warrants, a move analysts see as crucial for fueling the rapid growth of its IM8 wellness brand.

Gyre Therapeutics secures a pivotal conditional approval pathway in China for its novel liver fibrosis drug, offering hope for millions of hepatitis B patients.

A new partnership aims to unlock the potential of a next-gen obesity drug by pairing it with advanced delivery tech to overcome historical hurdles.

With a key drug decision looming and a refocused strategy, Rocket Pharmaceuticals faces a critical audience at the J.P. Morgan Healthcare Conference.

A new drug could redefine life for polycythemia vera patients, replacing frequent, burdensome blood draws with a simple weekly self-injection.

Facing its lowest donation levels in two decades, the Red Cross offers a Super Bowl trip to spur giving as hospitals risk rationing critical blood supplies.

In a major win, Rockwell Medical extends its DaVita supply deal through 2026 with a price hike, underscoring the value of its reliable supply chain.

Sanofi is investing up to $2.56 billion in Earendil Labs' AI platform to discover next-gen bispecific antibodies for complex autoimmune diseases.

With key trials in brain and prostate cancer, Curasight heads to a top investor conference to showcase its dual-action theranostic technology.

Abingworth elevates Bali Muralidhar and hires Travis Wilson, signaling a major push into clinical co-development and buyouts under Carlyle's wing.

International Petroleum Corp. is ahead of schedule and on budget at its massive Blackrod oil sands project, signaling a major win for Canadian energy.

Health Canada has approved JERAYGO, the first new hypertension drug class in 30 years, offering a lifeline to patients with hard-to-treat high blood pressure.

Legence completes its acquisition of The Bowers Group, creating a dominant force in mission-critical building systems for the DC area and beyond.